BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33632562)

  • 1. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
    Khanna M; Rady H; Dai G; Ramsay AJ
    Vaccine; 2021 Mar; 39(12):1780-1787. PubMed ID: 33632562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
    Deng YH; He HY; Zhang BS
    J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model.
    Pinpathomrat N; Bull N; Pasricha J; Harrington-Kandt R; McShane H; Stylianou E
    Vaccine; 2021 Mar; 39(9):1452-1462. PubMed ID: 33549390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
    Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
    Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations.
    Morelli MP; Del Medico Zajac MP; Pellegrini JM; Amiano NO; Tateosian NL; Calamante G; Gherardi MM; García VE
    Front Cell Infect Microbiol; 2020; 10():581812. PubMed ID: 33072631
    [No Abstract]   [Full Text] [Related]  

  • 10. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
    Dietrich J; Andersen C; Rappuoli R; Doherty TM; Jensen CG; Andersen P
    J Immunol; 2006 Nov; 177(9):6353-60. PubMed ID: 17056566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis.
    Ji P; Hu ZD; Kang H; Yuan Q; Ma H; Wen HL; Wu J; Li ZM; Lowrie DB; Fan XY
    Immunol Res; 2016 Feb; 64(1):64-72. PubMed ID: 26111521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice.
    Hu Z; Wong KW; Zhao HM; Wen HL; Ji P; Ma H; Wu K; Lu SH; Li F; Li ZM; Shu T; Xu JQ; Lowrie DB; Fan XY
    Mol Ther; 2017 May; 25(5):1222-1233. PubMed ID: 28342639
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Jia Q; Masleša-Galić S; Nava S; Horwitz MA
    mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.
    Dou J; Wang Y; Yu F; Yang H; Wang J; He X; Xu W; Chen J; Hu K
    Int J Immunogenet; 2012 Apr; 39(2):183-90. PubMed ID: 22152009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis.
    Young SL; Slobbe LJ; Peacey M; Gilbert SC; Buddle BM; de Lisle GW; Buchan GS
    Immunol Cell Biol; 2010 Aug; 88(6):651-7. PubMed ID: 20231853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.
    Dai FY; Wang JF; Gong XL; Bao L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.